In a recent excellent Review 1 (Bile acidmicrobiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111-128 (2018)), the connection between human and micro bial bile acid (BA) metabolism was described. In this Review, the authors identified possible therapeutic targets from data published in the context of gastrointestinal inflammation and carcinogenesis. From the microbial point of view, BAs are one of the main factors deter mining probiotic survival through the human gastrointestinal tract, which indeed was the focus of my PhD work 2 . In this regard, I feel that one important process as part of the interaction between BAs and probiotic bacteria is missing in the global picture presented in this Review: at least two of the main probiotic representatives, bifido bacteria and lactobacilli, accumulate primary unconjugated BAs (such as cholic acid (CA)) and probably secondary unconjugated BAs (such as deoxycholic acid (DCA)) in their cyto plasm either spontaneously, or following intra cellular BA deconjugation 3, 4 . In the latter case, BAs are generated after the action of the bile salt hydrolase (BSH), a cytoplasmic enzyme catalysing the hydrolysis of a conjugated BA into its unconjugated and amino acid moieties. Unconjugated BA accumulation requires cell energization, reflecting the situation happen ing during transient probiotic growth in the gut. BAs are weak acids that are transported in their neutral form (protonated) into the bac terial cytoplasm, where they quickly dissociate, losing a proton and lowering the internal pH of the bacterium 5 . Indeed, the mechanisms of resistance to BAs and low pH values are con nected in the Bifidobacterium lactis species through the membranebound F 1 F 0 ATPase; the high activity of this enzyme compared with other bifidobacteria together with its intrinsic aerotolerance explains why B. lactis is predominant in probiotic foods containing live bifidobacteria 6 . Secondary BAs are produced from primary BAs by the action of the human gut micro biota 7 . For instance, CA is dehydroxylated at the C7 position by the enzymatic action of strains belonging to the genera Clostridium and Eubacterium, resulting in the formation of DCA 8 . As pointed out by the authors 1 , DCA is involved in the progression of colorectal cancer, notably in the context of obesity, which is also characterized by an ongoing lowgrade inflammatory status. Gut concentration of proinflammatory and procarcinogenic DCA is therefore directly related to the composition of the intestinal microbiota, but the levels of this secondary BA might be modified by pro biotic intake or by the presence of higher levels of resident bifidobacteria and/or lactobacilli. The hypothesis is that primary BAs seques tered in the cytoplasm of these bacteria will escape the portal circulation and the action of other microorganisms to produce secondary BAs. Nonconverted primary BAs would be eliminated with the faeces.
BA accumulation in bifidobacteria and lactobacilli, with many strains being consid ered as probiotics and others representatives of the human gut microbiota, might have implications in chronic inflammation and carcinogenesis through this BAaccumulation mechanism. For that reason, higher levels of these bacteria (and perhaps other BSH containing Grampositive bacteria) or regular probiotic intake could be an interesting means of reducing colonic DCA levels and pos sibly decreasing inflammation and colorectal cancer risk. In this sense, experimental data support the probiotic ability to reduce DCA levels in vitro 9 . This aspect is of paramount importance as probiotics (lactobacilli and bifidobacteria) might be used as a means of decreasing DCA levels through deconjugation of conjugated CA or DCA or accumulation of primary or secondary BAs, with both cases resulting in the sequestration of those BAs in the large intestine.
